The Facility's Capabilities

The new facility will consist of analytical and formulation labs as well as GMP manufacturing space. Our staff will support the development of drug products, providing much-needed assistance to help organizations successfully bring products for oral and topical delivery to market.

Our staff will also leverage its expertise to progress projects involving small molecules and the oral and topical delivery of biologicals (including live biotherapeutics and other microbiome-based therapeutics). Over the next three years, the site will create more than 100 jobs.

Excellence in Formulation Development and Specialist Clinical Manufacturing

Since opening its doors in 2002, SGS's Quay Pharma has carved out a reputation for excellence in formulation development and specialist clinical manufacturing. It has successfully completed over 300 projects for a global client base from its UK-based MHRA- and FDA-inspected facility. Having acquired Quay Pharma in late 2021, we are committed to extending its global reach and capacity moving forward.

Maireadh Pedersen, SGS's Quay Pharma's Commercial Operations Director, commented:

"This is an extremely exciting and at the same time a natural move for the company, as we have been working with a great many US clients for several years and have built up a strong and growing customer base in the country.

"Customers will benefit from our ability to support them from either location. Our understanding of the regulatory difference between the EU and the US will enable us to build the groundwork for the relevant quality requirements at an early stage. This allows our customers to efficiently transition through the clinical phases as they expand their clinical trial sites around the world.

"The Greater Boston facility will be one of the first facilities established in the US for the development and manufacture of live biotherapeutic finished dosages and SGS's Quay will be the first provider to support this type of manufacture for microbiome-based medicines in both Europe and the US."

For further information, please contact:

David Humphreys
Head of Preclinical Business Development
t: +44 (0) 7570 649 047

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

SGS SA published this content on 14 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2022 14:43:09 UTC.